科伦博泰生物-B：Sac-TMT在中国递交肺癌NDA，与默沙东合作优化调整

研究报告 Research Report 21 Aug 2024 科伦博泰生物-B Sichuan Kelun-Biotech Biopharmaceutical (6990 HK) Sac-TMT 在中国递交肺癌 NDA，与默沙东合作优化调整 NDA Submission of Sac-TMT Lung Cancer in China, Optimizing Pipeline Collaboration with Merck [Table_yemei 观点聚焦 1] Investment Focus | --- | --- | |-----------------------------------------------|---------------------| | [Table_Info] 维持优于大市 Maintain OUTPERFORM | | | 评级 | 优于大市 OUTPERFORM | | 现价 | HK$169.90 | | 目标价 | HK$200.10 | | HTI ESG | 3.0-3.0-3.0 | E-S-G: 0-5, (Please refer to the App ...